Search clinical trials for: BCMA-CD3 bispecific

Total 617 results

Genmab
AbbVie

Approved for marketing

Expanded Access Program for Epcoritamab

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-cell Lymphoma (HGBCL) | Grade 3B Follicular Lymphoma
Margaret Ragni
Health Resources and Services Administration (HRSA)

Terminated

The Hemophilia Inhibitor Prevention Trial

Hemophilia A Without Inhibitor

United States
Immunocore Ltd

Completed

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

Uveal Melanoma

Spain, United States, Germany, Canada, United Kingdom
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

Extranodal NK/T Cell Lymphoma, Nasal Type

China
David Ho
Bill and Melinda Gates Foundation; International AIDS Vaccine Initiative; The...

Completed

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

HIV-1-infection

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Stage IV Non-small Cell Lung Cancer

China
Federal Research Institute of Pediatric Hematology...

Active, not recruiting

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

B-ALL

Russian Federation
Hangzhou Hanx Biopharmaceuticals, Ltd.
Wuhan Hanxiong Bioscience, Ltd.

Active, not recruiting

Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Elpiscience Biopharma, Ltd.

Withdrawn

A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumor
University of Virginia

Active, not recruiting

Phase I EGFR BATs in Newly Diagnosed Glioblastoma

Glioblastoma | Glioblastoma Multiforme

United States
Akeso

Active, not recruiting

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
University of Virginia

Terminated

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

Breast Cancer Female | Leptomeningeal Metastases

United States
Bio-Thera Solutions

Completed

Evaluate the Pharmacokinetics of BAT2022 in Healthy Chinese Subjects

SARS-CoV-2 Infection

China
Akeso
Akesobio Australia Pty Ltd

Completed

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

Metastatic Cervical Cancer | Recurrent Cervical Cancer

United States, Australia, New Zealand
Akeso
Akeso Pharmaceuticals, Inc.

Terminated

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
Akeso
Akeso Pharmaceuticals, Inc.

Active, not recruiting

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Gastric Adenocarcinoma | Advanced Solid Tumors | Gastroesophageal Junction Adenocarcinoma

China
Akeso
Akeso Pharmaceuticals, Inc.

Completed

A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Akeso
Akeso Pharmaceuticals, Inc.

Completed

Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

Melanoma | Advanced Solid Tumors

China
Akeso

Active, not recruiting

A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Solid Tumor, Adult

China
Pieris Pharmaceuticals, Inc.

Active, not recruiting

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

HER2-positive Gastric Cancer

United States, Korea, Republic of
Elpiscience Biopharma, Ltd.

Withdrawn

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors

Small Cell Lung Cancer | Non-small Cell Lung Cancer | Thoracic Tumors
Elpiscience Biopharma, Ltd.

Terminated

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumors | Malignant Tumor

China
Matthew C. Baker

Withdrawn

BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome (BAFF/IL-17)

Primary Sjogren's Syndrome

United States
Immunocore Ltd
Clinigen, Inc.

Available

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp (Non Applicable)

Uveal Melanoma
AstraZeneca

Completed

Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI7352 in Healthy Volunteers

Painful Osteoarthritis of the Knee

United Kingdom
Celgene

Completed

A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects

Healthy Volunteers

United States
Gilead Sciences
National Cancer Institute (NCI)

Withdrawn

Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
ABL Bio, Inc.
National OncoVenture

Completed

This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

Advanced Solid Tumors

Korea, Republic of
Eli Lilly and Company

Completed

A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer

Advanced Cancer

Belgium, United States, Korea, Republic of, Australia, France
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Beijing 302 Hospital

Unknown

Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

Advanced Liver Cancer

China
Biocad

Completed

First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects

Healthy

Russian Federation
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Cancer Ovaries | Cancer Peritoneal | Cancer, Fallopian Tube

United States
OncoMed Pharmaceuticals, Inc.

Terminated

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Advanced Solid Tumor Malignancies

United States
Immunocore Ltd

Completed

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Malignant Melanoma

United Kingdom, United States
The Second Affiliated Hospital of Henan University...
First Affiliated Hospital of Wenzhou Medical University; Second Affiliated... and other collaborators

Unknown

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

CD19-positive ALL

China
Amgen Research (Munich) GmbH

Completed

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) (BLAST)

B-cell Acute Lymphoblastic Leukemia

Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, United Kingdom
Bayer

Completed

First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer

Prostatic Neoplasms

Germany, Austria
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Shenzhen Second People's Hospital

Unknown

Targeted T-cell Therapy in Solid Tumors

Malignant Solid Tumor

China
Engeneic Pty Limited
Johns Hopkins University

Unknown

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV)

Glioblastoma | Astrocytoma, Grade IV

United States
Margaret Ragni

Withdrawn

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform (INHIBIT)

Severe Hemophilia A

United States
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Refractory | B-Cell Lymphoma Stage I | Relapsed

China
University of Virginia
National Cancer Institute (NCI)

Unknown

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Terminated

Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia

B Cell Leukemia

China
AIO-Studien-gGmbH
Neovii Biotech

Completed

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas (CatuNeo)

Gastric Adenocarcinoma With Peritoneal Carcinomatosis | Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis | Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis

Germany
Stephen Harbarth
European Commission

Unknown

Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy (R-GNOSIS WP3)

Intestinal Colonization With Multidrug-resistant Bacteria

Israel, Switzerland, France, Netherlands
Amgen Research (Munich) GmbH

Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States, United Kingdom, Germany, Spain, France, Italy
Biocad

Completed

First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-121 in Healthy Subjects

Healthy
Amgen Research (Munich) GmbH

Completed

Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

B-ALL

Germany

Search clinical trials for: BCMA-CD3 bispecific

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations